@article { WOS:000349723300017,
	title = {Scientific considerations concerning the EMA change in the definition of {\textquoteleft}{\textquoteleft}dose{{\textquoteright}{\textquoteright}} of the BCS-based biowaiver guideline and implications for bioequivalence},
	journal = {INTERNATIONAL JOURNAL OF PHARMACEUTICS},
	volume = {478},
	number = {2},
	year = {2015},
	month = {JAN 30},
	pages = {606-609},
	publisher = {ELSEVIER SCIENCE BV},
	type = {Article},
	address = {PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS},
	abstract = {This work discusses the scientific aspects of the definition of dose as the {\textquoteleft}highest single oral IR dose{\textquoteright} recommended for administration in the SmPC (summary of product characteristics) in the current European Medicines Agency (EMA) 2010 Guideline, for the purpose of biopharmaceutics classification system (BCS)-based biowaiver decision making. Analysis of theoretical and experimental data dealing with drug dissolution and biopharmaceutic drug classification reveals that the drug dose is an important parameter for both drug dissolution and biopharmaceutic classification. The relevant implications for the dose considerations in bioequivalence studies are also discussed briefly. It is suggested that the concept of {\textquoteleft}{\textquoteleft}the highest single dose oral IR dose recommended for administration in the SmPC{{\textquoteright}{\textquoteright}} of the EMA 2010 Guideline be abolished. It is advisable, each dose strength be considered separately Le., whether or not it meets the solubility-dissolution regulatory criteria. (C) 2014 Elsevier B.V. All rights reserved.},
	keywords = {BCS, bioequivalence, Dose, EMA, Guideline},
	issn = {0378-5173},
	doi = {10.1016/j.ijpharm.2014.11.062},
	author = {Daousani, Chrysa and Macheras, Panos}
}
